Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Can European Efficiency Measures Boost Generics And Biosimilars? – An Interview With EGA’s Adrian van den Hoven

Executive Summary

EGA Director General Adrian van den Hoven will call on the new European Commission and Parliament to introduce efficiency policies to increase the uptake of and access to generic drugs and biosimilars.

You may also be interested in...

Biosimilars Uptake In EU Could Slow If Innovators Switch Pricing Strategy

Austerity has driven biosimilars in Europe, but IMS strategist cautions that further saving could be mercurial because of ancillary costs.

EU Pricing Pressures On Generics And Biosimilars Risk Killing Industry –EGA Execs

New EGA president and director general say Europe must end downward pricing pressures on generic medicines manufacturers or risk losing that industry altogether.

Generics Firms Culled In Germany As Discount Contracts Bite

Germany’s discount contracts have secured huge savings for health insurers and the government, but are forcing generics manufacturers to reduce portfolios or leave the market altogether.

Related Content


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts